Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

FHS
May 22, 2024
9:55 am

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women’s health, with a deal value of up to £465,000.

Single-cell profiling reveals immune cell marker and regulator of anti-tumor immunity

B cells are thought to play a critical role in innate and adaptive immunity, but their exact role in anti-tumor immunity remains unknown.

June 24, 2023

Eternal youth? Chemical cocktails prove effective in cell age reversal

Researchers identified chemical drug combinations that could reverse cellular aging.

July 19, 2023

Opinion | Stroke Doesn’t Have to Lead to Death or Disability

Jayaraman is an interventional neuroradiologist. Imagine having a severe, life-threatening stroke at 5 p.m., being rushed by ambulance to undergo minimally invasive surgery to remove

September 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.